AlzeCure Pharma Past Earnings Performance
Past criteria checks 0/6
AlzeCure Pharma has been growing earnings at an average annual rate of 9.7%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually.
Key information
9.7%
Earnings growth rate
19.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | n/a |
| Return on equity | -100.4% |
| Net Margin | n/a |
| Next Earnings Update | 27 Feb 2025 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How AlzeCure Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -36 | 11 | 25 |
| 30 Jun 24 | 0 | -36 | 11 | 26 |
| 31 Mar 24 | 0 | -37 | 11 | 28 |
| 31 Dec 23 | 0 | -37 | 11 | 28 |
| 30 Sep 23 | 0 | -38 | 10 | 29 |
| 30 Jun 23 | 0 | -42 | 10 | 32 |
| 31 Mar 23 | 0 | -53 | 10 | 43 |
| 31 Dec 22 | 0 | -56 | 10 | 46 |
| 30 Sep 22 | 0 | -68 | 10 | 58 |
| 30 Jun 22 | 0 | -73 | 10 | 63 |
| 31 Mar 22 | 0 | -67 | 10 | 57 |
| 31 Dec 21 | 0 | -78 | 11 | 67 |
| 30 Sep 21 | 0 | -73 | 11 | 62 |
| 30 Jun 21 | 0 | -78 | 10 | 68 |
| 31 Mar 21 | 0 | -81 | 10 | 71 |
| 31 Dec 20 | 0 | -71 | 9 | 62 |
| 30 Sep 20 | 0 | -69 | 9 | 61 |
| 30 Jun 20 | 0 | -61 | 8 | 53 |
| 31 Mar 20 | 0 | -53 | 7 | 46 |
| 31 Dec 19 | 0 | -51 | 6 | 45 |
| 30 Sep 19 | 0 | -48 | 5 | 44 |
| 30 Jun 19 | -2 | -40 | 4 | 38 |
| 31 Mar 19 | -1 | -38 | 4 | 37 |
| 31 Dec 18 | 0 | -36 | 3 | 37 |
| 30 Sep 18 | 1 | -28 | -3 | 34 |
| 31 Dec 17 | 1 | -10 | 1 | 10 |
Quality Earnings: AC6 is currently unprofitable.
Growing Profit Margin: AC6 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AC6 is unprofitable, but has reduced losses over the past 5 years at a rate of 9.7% per year.
Accelerating Growth: Unable to compare AC6's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AC6 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Return on Equity
High ROE: AC6 has a negative Return on Equity (-100.41%), as it is currently unprofitable.